Real-world Efficacy Analysis of Combined Chinese and Western Medicine in the Treatment of Extensive-stage Small Cell Lung Cancer  

作　　者：Kai Tan Changhui Zhang Puhua Zeng 

机构地区：[1]Hunan University of Chinese Medicine,Changsha 410208,Hunan Province,China [2]Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine,Changsha 410006,Hunan Province,China [3]Hunan Academy of Traditional Chinese Medicine Affiliated Hospital,Changsha 410006,Hunan Province,China

出　　处：《Proceedings of Anticancer Research》2024年第6期198-208,共11页抗癌研究

基　　金：National Natural Science Foundation of China(Project No.:82074425);Young Qihuang Scholars Talent Project of National Administration of Traditional Chinese Medicine;Top Technology Leading Talents Project of Hunan Province;Key R&D projects in Hunan Province(Project No.:2021SK2006);Natural Science Foundation of Hunan Province(Project No.:2021JJ30417);Hunan Provincial Engineering Research Center of Anti-tumor Chinese Medicine Creation Technology Project;Hunan Provincial Health Commission Traditional Chinese Medicine Shennong Leading Talent Project。

摘　　要：Objective:To explore the efficacy of integrated traditional Chinese and Western medicine in the treatment of extensive-stage small cell lung cancer(ES-SCLC).Methods:Patients who were hospitalized and outpatients in the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine from April 1,2018,to April 1,2023,were selected and screened according to the inclusion and exclusion criteria.A total of 161 patients were included,of which the control group was chemotherapy combined with traditional Chinese medicine(TCM),and the experimental group was chemotherapy+immunotherapy combined with TCM.The primary endpoint of this study was overall survival(OS),and secondary endpoints included progression-free survival(PFS),objective remission rate(ORR),and disease control rate(DCR).SPSS 25.0 statistical software and R software(version 4.2.1)were used for processing and data analysis.Results:The prognosis of patients treated with chemotherapy+immunotherapy combined with TCM was significantly better than that of the chemotherapy combined with TCM group,with median OS(15.07 months vs.13.3 months,P=0.02)and median PFS(6.87 months vs.5.97 months,P=0.04).Conclusion:Based on adjuvant therapy with TCM,chemotherapy combined with immunotherapy has more advantages than chemotherapy alone in prolonging the median OS and PFS.It can improve the general condition of patients after treatment,enhance their tolerance,and provide basic guarantees for subsequent treatment.

关 键 词：Extensive-stage small cell lung cancer(ES-SCLC) Real-world study(RWS) IMMUNOTHERAPY CHEMOTHERAPY Traditional Chinese medicine(TCM) 

分 类 号：R73[医药卫生—肿瘤]